GlobeNewswire by notified

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Share
  • Mucosal route induces both localized and systemic immunity
  • Intravacc is currently developing 3 OMV-based intranasal vaccines
  • Article published in peer-reviewed journal ‘Current Opinions in Immunology’

BILTHOVEN, Netherlands, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Intravacc, a leading Contract Development and Manufacturing Organization (CDMO) specializing in translational research and the development of preventive and therapeutic vaccines, has announced the publication of a review on the efficacy of intranasally administered outer membrane vesicle (OMV)-based vaccines. The paper presents promising results in combatting various emerging and potentially fatal infectious diseases that infiltrate mucosal tissues, such as the oral, nasal, and urogenital surfaces. The review article has been published in the peer-reviewed journal ‘Current Opinion in Immunology' Volume 84, 2023.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Dr. Peter van der Ley, senior scientist of Intravacc and lead author,stated:

“Our review showcases OMVs' potential in mucosal immunization. They prompt robust local and distant immune responses. This offers a new angle for battling infectious diseases."

The review article highlights OMVs, released from Gram-negative bacteria, as promising vaccine candidates. They can carry diverse antigens, including those from viruses and bacteria, making them a versatile vaccine platform, especially when administered intranasally. By targeting the mucosal route, vaccines can induce both localized and systemic immunity. The findings, backed by animal trials, demonstrate OMV-based vaccines' efficacy against various pathogens. They also stress the safety and feasibility of intranasal delivery as an alternative to needles. The review points to ongoing clinical trials. OMV-based vaccines fuel optimism for innovative vaccine strategies that tap into mucosal immunity’s untapped potential.

Dr. Jan Groen, Intravacc’s CEO, says:

“As a CDMO, we are presently developing three OMV-based intranasal vaccines to address bacterial and viral infections for diverse customers. This illustrates the extensive potential of our OMV platform technology, which can also be harnessed for therapeutic vaccines, including those for cancer.”

About Intravacc’s OMV platform technology

For the development of vaccines, Intravacc has designed and developed a platform based on OMVs - spherical particles with intrinsic immune-stimulating properties. The OMVs can be designed with immunogenic peptides and/or proteins that stimulate effective adaptive immunity. The OMV carrier has been optimized to induce a more effective immune response against these newly introduced antigens. Intravacc has also developed genetic tools to increase the yield of the OMVs, reduce the toxicity and achieve the desired antigenic composition. Intravacc's OMV platform is scalable and allows rapid and efficient modification of the antigen composition, either through genetic modification of the bacterial host or by associating antigens with stored OMVs.

Watch the animation about Intravacc's Avacc® 10 intranasal COVID Vaccine

About Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global CDMO for infectious diseases and therapeutic vaccines. As an established independent CDMO with many years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology world-wide for many vaccines including polio, measles, DPT, Hib and influenza. Approximately 30% of childhood disease vaccines are based on Intravacc’s know-how and proprietary technology. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies for partners around the world, including biotech and pharmaceutical companies, governmental agencies and NGOs. With its innovative vaccine platforms OMV-VaccT, Cell-VaccT, Con-VaccT, E.co-VaccT and good manufacturing procedures (GMP) facilities the company is well positioned to address the unmet needs in the vaccine and immune therapy market.

Click here for the full article.

For more information, please visit www.intravacc.nl.

Contact info
Intravacc B.V.
Dr. Jan Groen, CEO
P: +31 30 7920 454

Sander Hagemans, Media relations
P: +31 30 7920 579
E: press.office@intravacc.nl

An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2c233c1-52f2-4670-921a-e0e4b097bf59

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis30.11.2023 18:23:37 CET | Press release

Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis Recruitment led by Grenoble Alpes University Hospital, driven by strong clinical sites participation and investigator support Topline data expected in Q4 2024 Paris (France), November, 30th 2023 – NH TherAguix a Phase 2 biotech company developing AGuIX®, an innovative nanodrug to improve cancer treatment by radiotherapy, announces the completion of recruitment in its NANORAD 2 Phase 2 clinical trial, randomized, multi-center study assessing safety and efficacy of AGuIX® in combination with whole brain radiation therapy versus whole brain radiation therapy alone, in adult patients with multiple brain metastasis. NANORAD 21 is a prospective randomized (1:1) open label trial with a total of 100 patients recruited in 14 active centers coordinated by Dr Camille Verry (CHUGA, Grenoble-Alpes, France) as principal investigator. This trial combines the rad

Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion30.11.2023 18:00:00 CET | Press release

Press release Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion: the company joins the CEO Action for Diversity & Inclusion™ Initiative; Vantiva has reduced the gender pay gap to 1% as of October 2023. Paris – November 30, 2023 – Vantiva (Euronext Paris: VANTI - formerly known as Technicolor), a global technology leader providing innovative technologies to Network Service Providers (NSPs) that connect consumers around the world, today announced that Chief Executive Officer Luis Martinez-Amago has joined the CEO Action for Diversity & Inclusion™ program, alongside more than 2,400 other business leaders. Signatories of the collective have already shared more than 1,900+ best-known actions, exchanging tangible learning opportunities and creating collaborative conversations via the initiative’s unified hub, CEOAction.com. By participating in this initiative, Vantiva confirms its commitment to taking steps to provide a working environment that respects different view

BW Energy: Mandatory notifications of trade by primary insiders and close associates30.11.2023 17:30:00 CET | Press release

Mandatory notifications of trade by primary insiders and close associates Reference is made to the announcements on 16 November 2023 and 28 November 2023, whereby BW Offshore Limited announced information relating to dividend payments. Please see the attached notifications of trading for information of transactions concerning primary insiders in BW Energy Limited ("BW Energy") and their close associates in connection with the dividend distribution. Further, reference is also made to the announcement on 30 November 2023, whereby it was announced that BW Group Limited purchased 250,000 shares in BW Energy. Please see the attached notification of trading for information of the transaction concerning primary insiders in BW Energy and their close associates in connection with the share purchase of 250,000 shares. For further information, please contact: Knut R. Sæthre, CFO BW Energy +47 91 11 78 76 ir@bwenergy.no About BW Energy: BW Energy is a growth E&P company with a differentiated strat

International Petroleum Corporation Updated Share Capital30.11.2023 17:30:00 CET | Press release

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of 427,400 common shares repurchased by IPC under the normal course issuer bid / share repurchase program, the total number of issued and outstanding common shares of the Corporation is 128,224,820 common shares with voting rights as at November 30, 2023, and IPC holds no common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Reb

Notice of extraordinary general meeting in IDEX Biometrics on 21 December 202330.11.2023 17:30:00 CET | Press release

IDEX Biometrics ASA will hold an extraordinary general meeting on Thursday 21 December 2023 at 12.00 hours CET as an online meeting. There is no physical attendance option. Shareholders may attend online. by PC, smartphone or tablet. The notice with attendance form will be sent to the shareholders today and is also enclosed in pdf file (links to notice, bilingual, and attendance form, English and Norwegian, below). The extraordinary general meeting will consider and resolve Share consolidationIssuance of convertible loan (ref notice to the market on 7 November 2023)Renewal of the customary authorizations to the board to issue sharesAmendment of the 2023 subscription rights incentive plan The notice of the annual general meeting and the ancillary documents are/will be available at the company's web site, www.idexbiometrics.com, and can be requested from the company at no charge from ir@idexbiometrics.com . For further information contact: Marianne Bøe, Investor Relations E-mail: mariann